Drug Profile
Remdesivir - Gilead Sciences
Alternative Names: Captisol-enabled remdesivir; Captisol®-enabled GS 5734; GS-5734; Redyx; VEKLURY; VekluryLatest Information Update: 07 Feb 2024
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Developer Capital Medical University; China-Japan Friendship Hospital; Chinese Academy of Medical Sciences; Dr Reddys Laboratories; Gilead Sciences; INSERM; National Institute of Allergy and Infectious Diseases; NeuroActiva; Roche
- Class Adenine nucleotides; Amines; Antivirals; Esters; Furans; Nitriles; Phosphorus compounds; Pyridazines; Pyrroles; Small molecules; Triazines
- Mechanism of Action RNA replicase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
- Phase III COVID-19 pneumonia
- Phase II Ebola virus infections
- No development reported Neurological disorders
Most Recent Events
- 11 Oct 2023 Efficacy data from a phase III REDPINE trial in Covid-19 infections presented at the IDWeek 2023 (IDW-2023)
- 11 Oct 2023 Pooled adverse events data from a phase III ACTT-1 trial, phase III PINETREE trial, phase III REDPINE trial presented at the IDWeek 2023 (IDW-2023)
- 19 Sep 2023 European Medicines Agency (EMA) grants positive opinion to extend the use of remdesivir to treat people with COVID-2019 infections (with mild to severe hepatic impairment)